SCHEMBL1107284

SCHEMBL1107284

CC(C)P1(=O)OCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14717330 0.73
SCHEMBL4763204 0.71
SCHEMBL14684695 0.70
SCHEMBL22639122 0.69
SCHEMBL8491395 0.67
SCHEMBL15557458 0.63
SCHEMBL17146589 0.62
SCHEMBL787556 0.62
SCHEMBL1107281 0.61
SCHEMBL11505488 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023204822-A1 PHENYL PHOSPHINE OXIDE COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
US-20130029939-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2013-01-31 US disclosed
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 US disclosed
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
US-7910747-B2 Phosphonate and phosphinate pyrazolylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 US disclosed
US-7718687-B2 Dihydropyrrole derivatives; 3-{(2S)-4-(2,5-difluorophenyl)-1-[(dimethylamino)carbonyl]-2,5-dihydro- 1H-pyrrol-2-yl}phenyl dihydrogen phosphate; anticarcinogenic agents; cellular proliferative diseases; specificity; side effect reduction MERCK SHARP & DOHME CORP., (US) 2010-05-18 US disclosed
US-7666862-B2 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer MERCK & CO., INC. (US) 2010-02-23 US disclosed
US-7638549-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropyrrolidin3-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents MERCK & CO. INC. (US) 2009-12-29 US disclosed
US-7622489-B2 Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl)-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-dihydro-1N-pyrrol-1-carboxamide MERCK & CO., INC. (US) 2009-11-24 US disclosed
US-7427637-B2 Mitotic kinesin inhibitors MERCK & CO. INC. (US) 2008-09-23 US disclosed
US-20080199459-A1 Mitotic Kinesin Inhibitors MERCK SHARP & DOHME CORP. 2008-08-21 US disclosed
US-7348440-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator MERCK & CO., INC. (US) 2008-03-25 US disclosed
US-20080039375-A1 Phosphorus-containing hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. 2008-02-14 US disclosed
US-20080039375-A1 Phosphorus-containing hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. 2008-02-14 US disclosed
US-7329762-B2 Prodrugs of mitotic kinesin inhibitors MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-20080027118-A1 Prodrugs Of Mitotic Kinesin Inhibitors MERCK SHARP & DOHME CORP. 2008-01-31 US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
US-7307085-B2 Kinesin spindle protein (KSP) inhibitors; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator; e.g. bicyclic dihydropyrrole derivatives MERCK & CO., INC. (US) 2007-12-11 US disclosed
US-7235580-B2 Mitotic kinesin inhibitors MERCK & CO., INC. (US) 2007-06-26 US disclosed